1. SWAG SSG Sarcoma Meeting
Clinical Research Network
West of England
SWAG SSG Sarcoma Meeting
Tuesday 2nd May 2017
Research Report

2. Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltshire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network

3. NIHR CRN High Level Objectives 2016-17
Increase number of participants into NIHR CRN portfolio studies
650,000 in England
21,905 in West of England
Increase the number of studies that deliver to time and target
Target 80%
Increase number of commercial studies delivered through network
Reduce NHS study set up times
Reduce time taken to recruit first participant

4. NIHR CRN Objectives for cancer 2016-17
Recruit 20% of cancer incidence
West of England 1,909
Recruit 7.5% of cancer incidence into interventional studies
716
Include challenging studies
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of year olds participating in research

7. Recruitment to Time and Target – Open Studies in April 2017

11. Cancer specialty objective for 2017-18
Number of LCRNs achieving on-target recruitment into at least 8 of the 13 Cancer subspecialties, where "on-target" means either improving recruitment by 10% from 2016/17 or meeting the following recruitment targets per 100,000 population served: 
a) Brain & CNS: 0.2; b) Breast: 8; c) Colorectal: 3; d) Paediatrics: 3; e) Gynae: 3; f) Head & Neck: 1; g) Haematology: 7; h) Lung: 4; i) Sarcoma: 0.1; j) Skin: 0.2; k) Supportive & Palliative Care and Psychosocial Oncology & Survivorship: 3; l) Upper GI: 3; m) Urology: 8.

12. 2016/17 YTD performance against 2017/18 Cancer specialty target

13. Open studies – Sarcoma CPMS ID Study Title Site Planned end date PI
19629
IMRiS: Phase II study of IMRT in primary bone and soft tissue sarcoma
Gloucestershire Hospitals NHS Foundation Trust
04/03/2018
Candish, Dr Charlie
11721
STRASS: A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcoma (RPS)
University Hospitals Bristol NHS Foundation Trust
09/01/2017
Ayre, Dr Gareth
13804
Euro Ewing 2012: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours
01/09/2024
Rees, Dr Helen
17239
rEECur: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
01/01/2020

14. Studies in set up CPMS ID Study Title Site PI Summary 19629
IMRiS: Phase II study of IMRT in primary bone and soft tissue sarcoma
University Hospitals Bristol NHS Foundation Trust
Ayre, Dr Gareth
IMRT is a well-established treatment that has been studied a great deal in other cancer types such as head and neck cancer where it has been shown to reduce side effects of radiotherapy, and some hospitals already use it to treat selected sarcoma patients. However, IMRT is not considered a routine treatment for sarcoma because it has not yet been tested properly in sarcoma clinical trials to prove that it is better than the usual way of giving radiotherapy.
30650
IDRIS: Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
Not Known
140 patients with newly-diagnosed SBP will be registered into the trial after radiotherapy. A bone marrow sample will be reviewed to check for 'high risk' features predictive of relapse. Patients with 'high risk' features will be randomised to have either lenalidomide and dexamethasone (group A1) or no further treatment (group A2). Patients with no 'high risk' features (group B) will also have no further treatment.

15. Useful links https://www.crn.nihr.ac.uk/
National and local network information including training programmes templates, tools, contacts, videos etc
Open data platform. Look at performance across whole CRN including all specialty areas
/csg.ncri.org.uk/portfolio/portfolio-maps/
View current national portfolio of open, closed and ‘in set up’ cancer studies
See where a study is open across the country
Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

16. Contacts Research Delivery Manager – david.rea@nihr.ac.uk
Cancer portfolio facilitator –
Sarcoma research lead –

17. Current Issues with Cancer Research
Gaps in the portfolio
Clinical pressures with some trial treatments
Pharmacy capacity issues
Extra time for administration of infusions
Extra length of treatment courses
Clinic space to see patients
Affordability to the NHS of the drugs we are researching
What should our regional portfolio look like?
Should we consider the whole region population when forecasting for trials?
Should we encourage more cross referral of patients for studies?
Should we select studies that will be more useful to the NHS?